Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage

INTERPACE BIOSCIENCES, INC.

Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.
Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.
Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.
Plan substantially complete by end of Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.